CSF2 and melanoma: Improved durable response rate (16.3 vs. 2.1%), overall response rate (26.4 vs. 5.7%), and longer median survival (23.3 vs. 18.9 months) in patients with non-surgically resectable melanoma receiving T-VEC vs. GM-CSF (9)